Since its introduction nearly 30 years ago, sentinel lymph node biopsy (SLNB) has become the standard technique to stage the axilla for the great majority of patients with early breast cancer. While the accuracy of SLNB in clinically node-negative patients who undergo neoadjuvant chemotherapy (NAC) is similar to the upfront surgery setting, modifications of the technique to improve the false negative rate are necessary in node-positive patients at presentation. Currently, patients who present with matted nodes, cN1 patients who fail to downstage to cN0 with NAC and those with pathological residual disease have an indication to undergo axillary lymph node dissection. Ongoing trials will confirm if extensive nodal irradiation can replace surgery in patients with residual nodal disease after NAC and if nodal radiotherapy can be omitted in patients who achieve nodal pathological complete response. The aim of this review was to focus on the open questions on the management of the axilla after NAC.

Axillary management after neoadjuvant treatment / Montagna, G.; Corso, G.; Di Micco, R.; van Den Rul, N.; Rocco, N.. - In: MINERVA CHIRURGICA. - ISSN 0026-4733. - 75:6(2020), pp. 400-407. [10.23736/S0026-4733.20.08600-9]

Axillary management after neoadjuvant treatment

Rocco N.
2020

Abstract

Since its introduction nearly 30 years ago, sentinel lymph node biopsy (SLNB) has become the standard technique to stage the axilla for the great majority of patients with early breast cancer. While the accuracy of SLNB in clinically node-negative patients who undergo neoadjuvant chemotherapy (NAC) is similar to the upfront surgery setting, modifications of the technique to improve the false negative rate are necessary in node-positive patients at presentation. Currently, patients who present with matted nodes, cN1 patients who fail to downstage to cN0 with NAC and those with pathological residual disease have an indication to undergo axillary lymph node dissection. Ongoing trials will confirm if extensive nodal irradiation can replace surgery in patients with residual nodal disease after NAC and if nodal radiotherapy can be omitted in patients who achieve nodal pathological complete response. The aim of this review was to focus on the open questions on the management of the axilla after NAC.
2020
Axillary management after neoadjuvant treatment / Montagna, G.; Corso, G.; Di Micco, R.; van Den Rul, N.; Rocco, N.. - In: MINERVA CHIRURGICA. - ISSN 0026-4733. - 75:6(2020), pp. 400-407. [10.23736/S0026-4733.20.08600-9]
File in questo prodotto:
File Dimensione Formato  
MontagnaG_RoccoN_Axillary_Managment_ After_ Neoadjuvant_Therapy copia.pdf

solo utenti autorizzati

Licenza: Copyright dell'editore
Dimensione 217.06 kB
Formato Adobe PDF
217.06 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/894656
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 3
  • ???jsp.display-item.citation.isi??? ND
social impact